Treatment of poxvirus infections in rabbits with 9-beta-D-arabinofuranosyladenine.
The antiviral efficacy of 9-beta-d-arabinofuranosyladenine (ara-A) was evaluated in localized lesions produced by the intradermal inoculation of rabbits with vaccinia virus (VV) and rabbit Shope fibroma virus (SFV). Ara-A administered intraperitoneally suppressed or significantly reduced the cutaneous pustular lesions produced by VV as well as the benign skin tumors caused by the SFV. With a daily dose of 300 mg/kg given for 5 days starting at the time of infection, or with 600 mg/kg daily starting 3 days after inoculation, we were able to suppress completely the formation of tumors induced by the SFV. The appearance of pustular lesions induced by VV was completely suppressed by a dose of 600 mg of ara-A per kg given for 3 days when the treatment was initiated at the time of infection, but a significant reduction in the number of pustular lesions was obtained with a single dose of 600 mg/kg, or with five doses of 300 mg/kg starting 24 h after inoculation. No toxic effect of ara-A was noted in the treated rabbits.
Klein
R J
RJ
Friedman-Kien
A E
AE
Brady
E
E
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D003872:Dermatitis / Q000188:drug therapy / Q000821:virology; D005260:Female; D012776:Fibroma Virus, Rabbit / Q000187:drug effects; D011213:Poxviridae Infections / Q000188:drug therapy; D011817:Rabbits; D014412:Tumor Virus Infections / Q000188:drug therapy; D014615:Vaccinia / Q000188:drug therapy* / Q000821:virology; D014616:Vaccinia virus / Q000187:drug effects*; D014740:Vidarabine / Q000494:pharmacology*
D000998:Antiviral Agents; D014740:Vidarabine